5 news items
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
CELU
19 Apr 24
of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
CELU
18 Apr 24
management, both in vitro and in vivo. The abstract focuses on assessing the biomaterials' biomechanical properties, immunomodulatory
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
CELU
15 Apr 24
, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
CELU
8 Apr 24
events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
CELU
20 Mar 24
as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements
- Prev
- 1
- Next